Biorestorative Therapies (BRTX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Maxim Group Maintains Biorestorative Therapies(BRTX.US) With Buy Rating, Raises Target Price to $8
Moomoo News13:31 ET · Ratings
Analysts Are Bullish on Top Healthcare Stocks: BioRestorative Therapies (BRTX), Rocket Pharmaceuticals (RCKT)
TipRanks13:00 ET · Ratings
BioRestorative Announces FDA Clearance Of IND for Phase 2 Trial Of BRTX-100 In Chronic Cervical Discogenic Pain
BenzingaFeb 27 09:47 ET
Express News | BioRestorative Announces Updated Time for February 27TH Webcasted Conference Call to Discuss Clinical Pipeline Update
ReutersFeb 26 20:15 ET
BioRestorative to Provide a Positive FDA Update on Clinical Pipeline
GlobeNewswireFeb 25 08:00 ET
BioRestorative Receives FDA Fast Track Designation For BRTX-100 Program For Chronic Lumbar Disc Disease
BenzingaFeb 20 08:31 ET

Comments

Teddy123

Feb 27 09:19

Biotech analysis

$Biorestorative Therapies (BRTX.US)$
BioRestorative's FDA clearance for their BRTX-100 IND in chronic cervical discogenic pain represents a significant clinical and strategic expansion that could substantially enhance the company's market position in regenerative medicine for spinal conditions.
This development is particularly noteworthy for three key reasons:
BRTX-100 becomes the first and only stem cell therapy cleared for evaluation in cervical degenerative disc disease, esta...

1

This_Guy

Feb 27 08:48

$Biorestorative Therapies (BRTX.US)$
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

Teddy123

Feb 27 08:47

BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain

$Biorestorative Therapies (BRTX.US)$
First-Ever Stem Cell Treatment for Neck Pain Gets FDA Green Light - What Makes BRTX-100 Revolutionary?

Jaguar8

Feb 27 08:45

NEWS

$Biorestorative Therapies (BRTX.US)$
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
Thursday, 27th February at 9:45 am
– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting –
– IND clearance expands Company's advanced clinical pipeline for BRTX-100 treatment of both chronic lower back and neck pain –
– Company to host webcasted conference call today...

3

102698073

Feb 27 03:11

$Biorestorative Therapies (BRTX.US)$ 27 feb 🚀🚀

BRTX Biorestorative Therapies

Trade Overview

Capital Trend

News

Comments

Trending Stocks